Fibrin and the vessel wall
- PMID: 2102620
- DOI: 10.1007/978-1-4615-3806-6_33
Fibrin and the vessel wall
Abstract
Fibrin is a major component of atherosclerotic plaques, and there may also be situations in which intravascular fibrin is formed in contact with the endothelium. The studies to be presented describe the distribution of fibrinogen/fibrin I, fibrin II, and fragments D and D-dimer in normal vessels and atherosclerotic plaques of increasing severity and also describe some functional effects of fibrin on normal endothelium. Immunohistochemical studies using three specific monoclonal antibodies with the avidin-biotin complex immunoperoxidase technique demonstrated that little fibrinogen/fibrin I or fibrin II and no D/D-dimer were detected in normal aortas. In early lesions and in fibrous plaques, fibrinogen/fibrin I and fibrin II were distributed in long threads and around vessel wall cells. D/D-dimer was not seen in early lesions. In advanced plaques all three molecular forms were detected in areas of loose connective tissue, in thrombi, and around cholesterol crystals. Thus increased fibrin formation and degradation may be associated with progression of atherosclerotic disease. Additionally, the presence of fibrin II around vessel wall cells suggests that these cells may be involved in the fbgn to fibrin transition within the vessel wall. The second aspect of the work to be presented concerns effects of fibrin on vascular endothelium. Fibrin formed on the surface of cultured human umbilical vein endothelial cells stimulated production of prostacyclin and tissue plasminogen activator by the cells in a time- and dose-dependent manner. Stimulation of prostacyclin was completely inhibited by indomethacin and partially inhibited by actinomycin D, cycloheximide, and trifluoperazine, while stimulation of t-PA synthesis was completely inhibited by actinomycin D and cycloheximide and partially inhibited by cytochalasin D, vinblastine, and trifluoperazine.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Effect of fibrin on endothelial cell production of prostacyclin and tissue plasminogen activator.Arteriosclerosis. 1989 Jan-Feb;9(1):43-9. doi: 10.1161/01.atv.9.1.43. Arteriosclerosis. 1989. PMID: 2492187
-
Identification and distribution of fibrinogen, fibrin, and fibrin(ogen) degradation products in atherosclerosis. Use of monoclonal antibodies.Arteriosclerosis. 1989 Jan-Feb;9(1):109-21. doi: 10.1161/01.atv.9.1.109. Arteriosclerosis. 1989. PMID: 2643421
-
Thrombosis in atherogenesis.Crit Rev Oncol Hematol. 1989;9(4):305-18. doi: 10.1016/s1040-8428(89)80016-2. Crit Rev Oncol Hematol. 1989. PMID: 2688680 Review.
-
Fibrinogen, fibrin and fibrin degradation products in relation to atherosclerosis.Clin Haematol. 1986 May;15(2):355-70. Clin Haematol. 1986. PMID: 3524931 Review.
-
[Effects of fibrinogen, fibrin and their degradation products on the behaviour of vascular smooth muscle cells].Nihon Ronen Igakkai Zasshi. 2000 Jun;37(6):458-63. doi: 10.3143/geriatrics.37.458. Nihon Ronen Igakkai Zasshi. 2000. PMID: 10998926 Review. Japanese.
Cited by
-
A Significance of High Prevalence of Diabetes and Hypertension in Severe COVID-19 Patients.J Clin Med Res. 2020 Jun;12(6):389-392. doi: 10.14740/jocmr4218. Epub 2020 Jun 4. J Clin Med Res. 2020. PMID: 32587655 Free PMC article. No abstract available.